Exponents International presented its experiences in Conference on innovation and biotechnology

Exhibitors of Conference international organized by AmCham. Photo: CREATECH.

Exhibitors of Conference international organized by AmCham. Photo: CREATECH.

The day 14 November was held in Santiago de Chile, the "Conference international innovation and biotechnology: Connecting with the world". The meeting organized by image of Chile and the Camera Chileno-Norteamericana of Commerce AmCham Chile, gathered around of 200 Professional and students linked to the innovation and to the biotechnology and counted with the participation of important exhibitors foreign and national. Then we tell you what tried this activity, supported by CORFO and attended part of the team of CREATECH.

The Welcome to the Conference was to charge of William Carey, Director and President of the Innovation Committee of AmCham Chile, Myriam Gómez, Executive Director of image of Chile, and Marcela angle, Manager of technological capabilities of CORFO. The latter referred to the way in which innovation in Chile is financed, Stressing that 2/3 of the investment it made the State and the universities, While only 1/3 the investment done by the private. For what is necessary to generate initiatives to connect the talent, existing mainly in universities, with the needs specific of the sector private.

After the welcome was the turn of Harvey Lodish, PhD in genetics, and among other things Member founder of the Whitehead Institute and President of the Council advisory scientific of the Massachusetts Life Science Center (MLSC). In his exhibition called "New Technologies, "Developing Drugs and Building Companies to Treat Diseases", spoke about his experience as a researcher and entrepreneur. Among the content mentioned was his experience as part of the team founder of 7 business start-ups, of which 5 still in operation: BioInformation Associates, Genzyme, ARRIS Pharma, The latest Rubius and Millenium Pharma. The key to the success of these, According to Lodish, is that the companies must be composed by experts of different areas. In his experience as a researcher, mainly of gene therapies for rare diseases, points out that these diseases delivered a tremendous opportunity for the development of the biotechnology. Thus is shown in the development current of a medication for the disease of Gaucher and a treatment for the phenylketonuria (PKU).

On the other hand said that the success of the MLSC, public-private initiative, in which you have invested to the date more than USD 390 million in projects of research and development, This is due to the support it has received for infrastructure, force work and its program of internships for students within these startups, many of which are are working in them.

The Conference continued with it talk "Building Effective Start-ups Ecosystems", by Tim Rowe, Founder and CEO of the Cambridge Innovation Center (CIC), Member of the Board of the New England Venture Capital Association and partner of the New Atlantic Ventures risk Capital. In his exhibition, Rowe stressed the importance of generating an innovation ecosystem, It is a collaborative structure so that it can develop. This so that the elements of the equation: ideas, talent and financing be mixed. On the other hand said that this collaborative network must be present and be active participants: teachers, investors, entrepreneurs and Government.

On the other hand said that you to be successful, the entrepreneurial team should be flexible and creative, usually the idea with which it begins is not that succeeds. This and the above complemented it by the example of how was born the Cambridge Innovation Center. Rowe said that initially the idea was to create multiple startups with the ideas of the founder, for what is hired to a CEO for each an in them, However after 18 months of development failed. This is translated in a change of model, is invited to entrepreneurs to develop their ideas transformed the space in a center of innovation. Currently is the largest installation to level world dedicated to this purpose, housing to 800 start-ups in 50 thousand m2 of offices shared. However, said that for these structures collaborative work, In addition to the elements mentioned, There must be trust between all stakeholders and clear rules that strengthen the.

To this chat you followed the "Panel ChileGlobal Biotec": "the challenge of exit to the market", in which prominent researchers counted on their experiences of successes in the field of the biotechnology in the foreign. The first in present it was Alberto Rodriguez-navarro, President and CEO of Levite Magnetics. Who said that its system of surgery bit invasive, that uses a clamp and an element magnetic, After performing the tests clinical in hospitals public of Chile, was approved by the FDA in United States and published in Annals of Surgery. This technology is in the process of application for patent of invention, to soon be marketed.

Then was the turn of Marco Cacciuttolo, Operations Manager of Batavia Biosciences, who spoke about his experience in several biotechnology startups, they were successful as MedImmune, which was sold to Astra Zeneca by close to USD 15 billion or Medarex, which was sold to Bristol-Myers Squibb in USD 2.4 thousand million. For frame, working in small businesses is more motivating that do so in large enterprises as the uncertainty of not having security in the future is what motivates innovation, as you learn to take risks.

Rafael Fernández finished panel, Principal Scientist-Pharmacology of Merck Research Laboratories, who has spearheaded investigations related to diabetes from different entities in the United States, metabolism in cell tumor, Immunology and immuno-Oncology. Although Fernandez, pointed out that, contrary to the framework, prefer to work in large companies, due to the security that these delivered allowing integrate ideas innovative without fear to the deadlines and the term of the funds, In addition to the team of people needed to develop projects, indicated that each company, independent of the size that this has, It must have its own model of development, every experience is different. But if is should integrate to the team a person expert in sales for to make profitable the innovation, Also coincides with their predecessors in the panel that in Chile is necessary to introduce the mentality of collaboration for the development successful of the innovation.

The event ended with the exhibition of Fernando Martinez, Advisor international of the program of biotechnology of CORFO, who in his talk "investment in biotechnology: "A need for the development of Chile", said that although Chile within Latin America has the largest index of knowledge, not is using all its capabilities, so it is in the search for a model that suits the country to develop the system of innovation in biotechnology.

Paula Escudero, Coordinator of communications and public relations of CREATECH, was present in the activity, commenting that "it was an interesting instance, Since different edges of innovation in general and in biotechnology were exposed in particular. "On the other hand allowed know experiences international and as came to be successful".


Related articles: